A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
CompletedCTIS2023-507895-36-00
Itb-Med ABRenal Transplantation
Start: 2021-06-06End: 2024-12-11Target: 33Updated: 2024-08-02